<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01515202</url>
  </required_header>
  <id_info>
    <org_study_id>MB121-009</org_study_id>
    <nct_id>NCT01515202</nct_id>
  </id_info>
  <brief_title>Japanese Phase 1 Multiple Ascending Dose Study</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Double-Blinded, Multiple Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-823778 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical study is to assess the safety and tolerability of multiple oral
      doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes
      Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MAD study - Multiple Ascending Dose study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability, as measured by the number, frequency and intensity of adverse events, vital sign measurements, ECGs, physical examinations, and clinical laboratory tests</measure>
    <time_frame>Up to Day 21</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Cmin) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve in one dosing interval [AUC(TAU)] of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation Index following multiple dosing (AI) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma half-life (T-HALF) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery (% UR) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance from plasma (CLR) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak to trough ratio (Cmax/Cmin) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective plasma half-life (T-HALFeff) of BMS-823778, as measured by plasma/urine concentration</measure>
    <time_frame>Up to Day 21</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics, as measured by Serum concentration of cortisol and cortisone after an oral dose of cortisone and biomarkers for HPA axis activity (urinary free cortisol and cortisone, salivary cortisol, ACTH, DHEA-S and 4-androstenedione)</measure>
    <time_frame>Up to Day 21</time_frame>
    <description>HPA = Hypothalamic-pituitary-adrenal
DHEA-S = Dehydroepiandrosterone-sulphate
ACTH = adrenocorticotropic hormone</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Panel 1: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 2: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 3: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy Subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 4: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with T2DM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Panel 5: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with T2DM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-823778</intervention_name>
    <description>Capsules, Oral, 2 mg, Once daily, 14 days</description>
    <arm_group_label>Panel 1: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_label>Panel 4: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-823778</intervention_name>
    <description>Capsules, Oral, 12 mg, Once daily, 14 days</description>
    <arm_group_label>Panel 2: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-823778</intervention_name>
    <description>Capsules, Oral, 25 mg, Once daily, 14 days</description>
    <arm_group_label>Panel 3: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-823778</intervention_name>
    <description>Capsules, Oral, 15 mg, Once daily, 14 days</description>
    <arm_group_label>Panel 5: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matching with BMS-823778</intervention_name>
    <description>Capsules, Oral, 0 mg, Once daily, 14 days</description>
    <arm_group_label>Panel 1: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_label>Panel 2: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_label>Panel 3: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_label>Panel 4: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
    <arm_group_label>Panel 5: BMS-823778 or Placebo matching BMS-823778</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese patients with Type 2 Diabetes Mellitus (T2DM) [Fasting glucose &lt; 240 mg/dL,
             Hemoglobin A1c (HbA1c): 6.5% to 10.0% National Glycohemoglobin Standardization Program
             (NGSP)] who are treatment-naive and managed with diet and/or exercises only, ages: 20
             to 65 years

        Exclusion Criteria:

          -  Patient who is taking any medication for T2DM

          -  Symptoms of poorly controlled diabetes that would preclude participation in this
             placebo-controlled trial

          -  Insulin therapy within one year of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hachioji-Shi</city>
        <state>Tokyo</state>
        <zip>1920071</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2012</study_first_submitted>
  <study_first_submitted_qc>January 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2012</study_first_posted>
  <last_update_submitted>December 4, 2012</last_update_submitted>
  <last_update_submitted_qc>December 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

